Sezary syndrome

WikiDoc Resources for Sezary syndrome
Articles
Most recent articles on Sezary syndrome Most cited articles on Sezary syndrome Review articles on Sezary syndrome Articles on Sezary syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sezary syndrome Images of Sezary syndrome Photos of Sezary syndrome Podcasts & MP3s on Sezary syndrome Videos on Sezary syndrome
Evidence Based Medicine
Cochrane Collaboration on Sezary syndrome Bandolier on Sezary syndrome TRIP on Sezary syndrome
Clinical Trials
Ongoing Trials on Sezary syndrome at Clinical Trials.gov Trial results on Sezary syndrome Clinical Trials on Sezary syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sezary syndrome NICE Guidance on Sezary syndrome NHS PRODIGY Guidance FDA on Sezary syndrome CDC on Sezary syndrome
Books
Books on Sezary syndrome
News
Sezary syndrome in the news Be alerted to news on Sezary syndrome News trends on Sezary syndrome
Commentary
Blogs on Sezary syndrome
Definitions
Definitions of Sezary syndrome
Patient Resources / Community
Patient resources on Sezary syndrome Discussion groups on Sezary syndrome Patient Handouts on Sezary syndrome Directions to Hospitals Treating Sezary syndrome Risk calculators and risk factors for Sezary syndrome
Healthcare Provider Resources
Symptoms of Sezary syndrome Causes & Risk Factors for Sezary syndrome Diagnostic studies for Sezary syndrome Treatment of Sezary syndrome
Continuing Medical Education (CME)
CME Programs on Sezary syndrome
International
Sezary syndrome en Espanol Sezary syndrome en Francais
Business
Sezary syndrome in the Marketplace Patents on Sezary syndrome
Experimental / Informatics
List of terms related to Sezary syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Sezary syndrome is one of the most common subtypes of cutaneous T cell lymphoma (CTCL).

Historical Perspective

• Sezary syndrome (SS) was first described by Albert Sézary.

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of sezary syndrom is exact unknown.
• In 2005 and 2009 the incidence of sezary syndrome was estimated to be 0/08-0/09 cases per 100,000 individuals in the United States.

Age

• [Disease name] is more commonly observed among patients aged [age range] years old.
• Sezary syndrome is more commonly observed among elderly patients.

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• Sezary syndrome usually affects individuals of the whites race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].